COMMUNIQUÉS West-GlobeNewswire

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
08/09/2026
Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels ACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE [...]
Prana Therapies Announces Positive Phase 1 Results for PRA-216, a Novel IL-4Rα/TSLP Bispecific Antibody, Supporting Its Potential Best-in-Disease Profile and Providing the First Clinical Validation of Prana’s INSPIRE Multispecific Platform
08/09/2026
Rapid, deep, and durable pharmacodynamic activity demonstrated across key Type 2 inflammatory biomarkers, including pSTAT6, TARC, eosinophils, and IgE Extended half-life and 85% subcutaneous bioavailability support the [...]
UK’s MHRA Accepts Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment
08/09/2026
LOR, the first approval-stage drug candidate with disease-modifying potential for osteoarthritis, is now under assessment in the United Kingdom, with a submission to the European Medicines Agency planned for later this [...]
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
08/09/2026
U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, [...]
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
Notice to Convene an Extraordinary General Meeting of Genmab A/S
08/09/2026
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be [...]
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
MediciNova to Participate in Two Investor Conferences in September
08/09/2026
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
08/09/2026
LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease
08/09/2026
Sabrina Kuttruff-Coqui appointed Chief Executive Officer, Joachim Koch appointed Chief Scientific and Development Officer and Andreas Muehler joining as Chief Medical Officer Expanded leadership team brings decades of [...]
Transactions in connection with share buy-back program
08/09/2026
Company announcement no. 34 - 26 08 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Du massage intelligent au bien-être proactif : SKG élargit sa gamme de dispositifs de santé portables à l’occasion de l’IFA 2026
08/09/2026
La présentation à Berlin associe la technologie de massage portable de SKG à la récupération, à l’accompagnement de l’entraînement et au suivi préventif de la santé BERLIN, 08 sept. 2026 (GLOBE NEWSWIRE) -- SKG Health [...]
From Smart Massage to Proactive Wellness: SKG Expands Its Wearable Health Portfolio at IFA 2026
08/09/2026
Berlin showcase connects SKG's portable massage technology with recovery, training support and proactive health monitoring BERLIN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SKG Health is showcasing an expanded portfolio of [...]
New Multi-Site Validation Study Published by Panakeia Reinforces Scalability of AI Multi-Omics Platform
08/09/2026
Study confirms diagnostic-grade performance of PANProfiler Breast (ER, PR, HER2) from routine brightfield images; establishing the technology as a scalable foundation for oncology across multiple cancer types and [...]
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
08/09/2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1 ) and exhaled [...]
First licensed treatment now available for condition behind the UK’s leading cause of horse euthanasia
08/09/2026
New veterinary treatment targets insulin dysregulation, the most common cause of laminitis in horses and ponies Bracknell, United Kingdom – Boehringer Ingelheim has announced the availability in Great Britain of the [...]
PannTheraPi Receives ANSM Approval to Advance PTI5803 into Phase 2a in Focal Cortical Dysplasia
08/09/2026
Phase 2a study to evaluate PannTheraPi’s first-in-class Pannexin 1-targeting therapy in patients with drug-resistant FCD, a rare and severe form of epilepsy Nîmes, France, 8 September 2026 — PannTheraPi , a clinical- [...]
PannTheraPi obtient l'approbation de l’ANSM pour l’entrée en Phase 2a de PTI5803 dans la dysplasie corticale focale
08/09/2026
L’étude de Phase 2a évaluera PTI5803, un traitement first-in-class ciblant le canal Pannexin1, chez des patients atteints de dysplasie corticale focale pharmacorésistante, une forme rare et sévère d’épilepsie Nîmes, le [...]
Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer
08/09/2026
Dr Ambarkhane brings proven 20+ year track record advancing innovative cancer therapies through clinical development and regulatory approval Appointment strengthens Cytospire's executive leadership team as the Company [...]

Pages